Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,396JPY
9 Dec 2016
Change (% chg)

¥6 (+0.25%)
Prev Close
¥2,390
Open
¥2,380
Day's High
¥2,405
Day's Low
¥2,368
Volume
3,707,100
Avg. Vol
2,505,273
52-wk High
¥2,750
52-wk Low
¥2,078

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.82
Market Cap(Mil.): ¥1,694,537.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.72

Financials

  4568.T Industry Sector
P/E (TTM): 26.95 29.74 30.35
EPS (TTM): 88.69 -- --
ROI: 3.71 15.90 15.27
ROE: 4.99 17.00 16.60

BRIEF-Portola Pharmaceuticals expands pact with Daiichi Sankyo

* Portola Pharmaceuticals expands clinical collaboration agreement with Daiichi Sankyo worth up to $25 million to develop ANDEXXA (Andexanet Alfa) in Germany

01 Nov 2016

BRIEF-Pieris Pharmaceuticals to receive GLP Tox payment in Daiichi Sankyo collaboration

* Pieris Pharmaceuticals to receive GLP tox milestone payment in Daiichi Sankyo collaboration

26 Oct 2016

BRIEF-Daiichi Sankyo Co and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond

* Daiichi And Inspirion Delivery Sciences LLC announce U.S. Licensing agreement for morphabond formulated with sentrybond abuse-deterrent technology

25 Oct 2016

BRIEF-Daiichi Sankyo completes 20.2 mln shares' buy-back for 50 bln yen

* Says it completes around 20.2 million shares' buy-back for approximately 50 billion yen as of Oct. 24

25 Oct 2016

BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration

* Daiichi Sankyo Co Ltd - co, Dana-Farber Cancer Institute today announced a preclinical research collaboration focused on lung cancer

12 Oct 2016

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

11 Oct 2016

BRIEF-Daiichi Sankyo Co enters into a collaboration with Agonox Inc

* Daiichi Sankyo and Agonox will collaborate on preclinical development of program of an undisclosed immuno-oncology target

04 Oct 2016

BRIEF-Daiichi Sankyo announces New Global Head of Development

* Daiichi Sankyo announces new global head of development Source text for Eikon: Further company coverage:

06 Sep 2016

BRIEF-Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen

* Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036

15 Jul 2016

BRIEF-Amgen and Daiichi Sankyo agree to commercialize Biosimilars in Japan

* Amgen and daiichi sankyo announce agreement to commercialize biosimilars in japan

14 Jul 2016

Earnings vs. Estimates